"Aminopyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.
| Descriptor ID |
D000631
|
| MeSH Number(s) |
D02.092.080 D03.383.725.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminopyridines".
Below are MeSH descriptors whose meaning is more specific than "Aminopyridines".
This graph shows the total number of publications written about "Aminopyridines" by people in this website by year, and whether "Aminopyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 0 | 3 |
| 2011 | 4 | 0 | 4 |
| 2012 | 2 | 2 | 4 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 5 | 4 | 9 |
| 2016 | 4 | 3 | 7 |
| 2017 | 6 | 4 | 10 |
| 2018 | 10 | 1 | 11 |
| 2019 | 5 | 5 | 10 |
| 2020 | 7 | 1 | 8 |
| 2021 | 8 | 7 | 15 |
| 2022 | 1 | 7 | 8 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aminopyridines" by people in Profiles.
-
Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024 Aug; 103(8):3083-3093.
-
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
-
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Adv. 2024 05 28; 8(10):2509-2519.
-
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leuk Res. 2024 05; 140:107497.
-
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study. Leuk Res. 2024 05; 140:107480.
-
Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis. Endocrinology. 2024 Feb 20; 165(4).
-
IDH2 mutations in acute myeloid leukemia. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1733-1741.
-
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Adv Ther. 2023 05; 40(5):2515-2523.
-
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. J Zhejiang Univ Sci B. 2022 Aug 15; 23(8):666-681.
-
Two-pore channel blockade by phosphoinositide kinase inhibitors YM201636 and PI-103 determined by a histidine residue near pore-entrance. Commun Biol. 2022 07 23; 5(1):738.